Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnpario Regulatory News (ANP)

Share Price Information for Anpario (ANP)

Share Price is delayed by 15 minutes
Get Live Data
520.00    5.00 (0.97%)
Bid:
510.00
Ask:
530.00
Spread: 20.00 (3.922%)
Market Cap: £85.47m
ANP Live PriceLast checked at - London Stock Exchange

Intraday Anpario Share Chart

AGM Statement

19 Jun 2025 07:00

RNS Number : 4973N
Anpario PLC
19 June 2025
 
Anpario plc("Anpario", "Group" or the "Company")

 

AGM Statement

 

 

Anpario plc, the independent manufacturer of natural sustainable animal feed additives for health, nutrition and biosecurity, is holding its AGM later today, at which Matthew Robinson, Chairman, will make the following statement:

 

"The Group achieved a strong sales performance in the first half of the year as our business development initiatives deliver and the global agriculture market improves. As such, we are confident of achieving market expectations* for the full year. There are challenges to navigate, however, and the current geopolitical environment makes it difficult to predict if and how our markets could be affected, but our geographic, species and product diversity should help to mitigate against any potential adverse impact.

 

We are particularly encouraged by a strong performance in the United States with a recovery in the sales of pHorce® to the swine sector and continued growth of Orego-Stim® in the organic egg layer and young cattle segments. India is also delivering a particularly strong performance. Brazil continues to disappoint due to tough local trading conditions.

 

The Group's business development initiatives include preparation to launch several Bio-Vet products, including leading brands RumenAider®, Generator™ and QuadriCal®, in various territories around the world. Initial discussions with customers and Anpario's global sales team are very encouraging and product registration work is now underway.

 

Following a strong end to 2024, we have been normalising our inventory levels to support the higher levels of activity seen at the end of last year and the continued growth in 2025. At the same time, we have seen a proportional increase in trade receivables which has absorbed further cash as well as a reduction in trade and other payables, leading to a slight reduction in overall cash. Our cash balance was £9.0m as at 31 May 2025 (£10.5m at 31 December 2024), representing a strong financial position with which to continue to grow the business, both organically and through acquisitions, should the right opportunities arise."

 

The Company's interim results for the six months period ended 30 June 2025 are expected to be announced on 10 September 2025.

 

 

*Analyst consensus for FY 2025 immediately prior to this announcement was Revenue of £44.8m, EBITDA of £7.6m and net cash of £11.9m.

 

 

 

Enquiries

 

Anpario plc

Richard Edwards, Chief Executive Officer

+44(0)7776 417 129

Marc Wilson, Group Finance Director

+44(0)1909 537 380

Shore Capital

 

(Nominated Adviser and Broker)

+44 (0) 20 7408 4090

Stephane Auton

Corporate Advisory

David Coaten

Tom Knibbs

Henry Willcocks

Corporate Broking

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMFFFSVRLITLIE
Date   Source Headline
13th Sep 20247:00 amRNSNotice of Investor Presentation
11th Sep 20247:00 amRNSInterim results
14th Aug 202411:22 amRNSDirector/PDMR Shareholding
18th Jul 20247:00 amRNSBlock listing Interim Review
25th Jun 20242:34 pmRNSResult of AGM
25th Jun 20247:00 amRNSAGM Statement
12th Jun 20244:11 pmRNSHolding(s) in Company
24th May 202410:04 amRNSPosting of Annual Report and Notice of AGM
21st Mar 202411:37 amRNSDirector/PDMR Shareholding
21st Mar 20247:00 amRNSDirector/PDMR Shareholding
5th Feb 20247:00 amRNSAward of Options and Director/PDMR Shareholding
24th Jan 20247:00 amRNSFull year trading statement
17th Jan 20247:00 amRNSBlock listing Interim Review
5th Oct 20239:23 amRNSDirector Disclosure
13th Sep 20237:00 amRNSHalf-year Report
25th Aug 20235:10 pmRNSBlock listing Interim Review
1st Aug 20237:00 amRNSDirectorate Change
10th Jul 20232:14 pmRNSHolding(s) in Company
7th Jul 20232:34 pmRNSHolding(s) in Company
29th Jun 20233:57 pmRNSResult of AGM
29th Jun 20237:00 amRNSAGM Statement
23rd Jun 20237:00 amRNSResult of Tender Offer
19th Jun 20232:48 pmRNSGM Statement
15th Jun 20237:00 amRNSShareholder Tour
7th Jun 20234:09 pmRNSReplacement - Tender Offer
6th Jun 20237:00 amRNSPosting of Annual Report and Notice of AGM
2nd Jun 20237:00 amRNSTender Offer
23rd May 20237:00 amRNSChange of Adviser
19th May 20234:40 pmRNSDirector Disclosures
19th May 20233:35 pmRNSTotal Voting Rights
5th May 20237:00 amRNSDirectorate Change
21st Apr 20237:00 amRNSAnpario receives King’s Award for Enterprise
11th Apr 20237:00 amRNSDirector/PDMR Shareholding
31st Mar 20231:13 pmRNSHolding(s) in Company
28th Mar 20237:00 amRNSDirector/PDMR Shareholding
22nd Mar 20237:00 amRNSFinal Results
3rd Feb 20237:00 amRNSDirector/PDMR Shareholding
24th Jan 202312:56 pmRNSBlock listing Interim Review
9th Jan 20237:00 amRNSFull Year Trading Statement
16th Dec 20227:00 amRNSAnpario receives ISO 14001 Certification
4th Nov 202212:52 pmRNSTotal Voting Rights
19th Oct 20227:00 amRNSDirector/PDMR Shareholding - Replacement
18th Oct 20227:00 amRNSDirector/PDMR Shareholding
6th Oct 20227:00 amRNSESG Initiatives
3rd Oct 20222:32 pmRNSDirector/PDMR Shareholding
14th Sep 20227:00 amRNSHalf-year Report
5th Sep 202212:38 pmRNSTotal Voting Rights
5th Aug 20222:00 pmRNSBob The Pigeon Back Home in Gateshead, Pet!
20th Jul 20221:02 pmRNSBlock listing Interim Review
7th Jul 20222:59 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.